Galapagos, Gilead Announce Global Partnership to Develop Filgotinib to Treat Rheumatoid Arthritis, Other Inflammatory Diseases

Loading...
Loading...
Galapagos NV
GLPG
and Gilead Sciences, Inc.
GILD
today announced that the companies have entered into a global partnership for the development and commercialization of the JAK1-selective inhibitor filgotinib for inflammatory indications.  Galapagos will receive an upfront payment of $725 million consisting of a license fee of $300 million and a $425 million equity investment in Galapagos.  In addition, Galapagos is eligible for payments of up to $1.35 billion in milestones, with tiered royalties starting at 20% and a profit split in co-promotion territories. Phase 2 trial data show that filgotinib has the potential to be an effective and well-tolerated oral therapy for patients with rheumatoid arthritis (DARWIN studies) and Crohn's disease (FITZROY study).  The companies will start Phase 3 trials in RA and Crohn's in 2016 pending the successful outcome of discussions with regulatory authorities. "We are excited about the potential of filgotinib in RA and other diseases with a strong partner like Gilead, which
See full press release
Posted In: NewsContractsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...